Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice
Open Access
- 26 January 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 48 (5) , 510-517
Abstract
Background: Evidence about tralokinumab treatment for moderate-to-severe atopic dermatitis (AD) in daily practice is limited. Aim: To report the first evidence, to our knowledge, from daily practice of treatment with tralokinumab in patients with AD. Methods: In this observational prospective study, patients with AD who received tralokinumab treatment in the context of routine care at the Erasmus Medical Centre were included between November 2021 and February 2022. This included 28 patients who had previously been treated with dupilumab, and 14 patients who had been treated with a Janus kinase inhibitor (JAKi). The Investigator’s Global Assessment (IGA; 0–4) and the numeric rating scale peak pruritus during the past 7 days (NRS itch 7d: 0–10), adverse events and reasons for discontinuation were analysed. A good clinical response was defined as any decrease in IGA and NRS itch 7d and if a patient was satisfied with the treatment and wished to continue with therapy. Results: In total, 37 patients were treated with tralokinumab. Twenty-two (59%) patients showed a good response to tralokinumab treatment. Fifteen (41%) patients discontinued treatment because of inadequate AD control or adverse events. Treatment-related adverse events were mild in most patients. Half of the patients where treatment with dupilumab had failed had a good clinical response to tralokinumab. Conclusions: Tralokinumab was found to be effective in most patients in this cohort with difficult-to-treat, severe AD from daily practice. Interestingly, tralokinumab was also found to be effective in 50% of patients who had previously experienced insufficient response or adverse events with dupilumab treatment.Keywords
This publication has 20 references indexed in Scilit:
- Atopic Dermatitis Is an IL-13–Dominant Disease with Greater Molecular Heterogeneity Compared to PsoriasisJournal of Investigative Dermatology, 2019
- Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitisThe Journal of Dermatology, 2017
- Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2Journal of Molecular Biology, 2017
- Systemic Treatment of Adult Atopic Dermatitis: A ReviewDermatology and Therapy, 2016
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016
- Atopic dermatitisThe Lancet, 2016
- Why do we need observational studies of everyday patients in the real-life setting?: Table 1European Heart Journal Supplements, 2015
- Cytokine profiles in interstitial fluid from chronic atopic dermatitis skinJournal of the European Academy of Dermatology and Venereology, 2015
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014
- Severity distribution of atopic dermatitis in the community and its relationship to secondary referralBritish Journal of Dermatology, 1998